Receiving Drugs Containing Selenium Does Not Reduce The Risk Of Lung Cancer – Part 2 of 3
But the redesigned study found that among more than 1,500 stage 1 (early) non-small cell lung cancer patients who had survived their initial bout with the disease, selenium offered no guardianship against recurrence or the onset of a new cancer or second primary cancer. The patients were tracked from 2000 to 2009, after all had undergone surgery to remove their initial tumors and remained cancer-free for a nominal of six months post-treatment.
Half the patients were placed on a regimen of 200 micrograms of selenium, while the other half took a placebo. Those in the placebo group had better survival rates five years later than those taking the end-piece – an observation that led the research team to halt the study earlier than planned.